Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction

Bibliography

• DAVIES MJ: A macro and micro view of coronary vascular insult in ischaemic heart disease. Circulation (1990) 82\(Suppl.3):I138–1146.
   Google Scholar
• FUSTER V, BADIMON L, BADIMON JJ, CHESEBRO JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl. I Med. (1992) 326:242-250, 310–318.
   PubMedGoogle Scholar
• RICHARDSON PD, DAVIS MJ, BORN GVR: Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet (1989) 2:941–944.
   PubMed Web of Science ®Google Scholar
• BLOCKMANS D, DECKMYN H, VERMYLEN J: Platelet activation. Blood Rev (1995) 9(3):143–156.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, PLOW EF, TOPOL EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Errg1.1. Med. (1995) 332:1553-1559. A comprehensivee review of a new class of antiplatelet agents as they emerged for the first time into the clinical arena.
   Google Scholar
• KROLL MH, HELLUMS JD, MCINTIRE LV et al..et al..: Platelets and shear stress. Blood (1996) 88(5):1525–1541.
   Google Scholar
• SCHAFER Al: Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. Texas Heart Inst. 1 (1997) 24:90–96.
   PubMed Web of Science ®Google Scholar
• COLLER BS: A new murine monoclonal antibody reports an activation dependent change in the conformation and/or microenvironment of the GP IIb/IIIa complex. ..I CM]. Invest. (1985) 76:101–108.
   PubMed Web of Science ®Google Scholar
• THEROUX P, KOUZ S, ROY L et al: Platelet membrane receptor glycoprotein IIb/ Ma antagonism in unstable angina Circulation (1996) 94(6):899–905.
   Google Scholar
• THE PARAGON INVESTIGATORS: International, randomised controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for Reduction of Acute coronary syndrome events in a Global Organisation Network. Circulation (1998) 97(24):2386–2395.
   Google Scholar
• MOLITERNO DJ: Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee. Am. Heart 1. (2000) 139(4):563–566.
   Google Scholar
• THE PARADIGM INVESTIGATORS: Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial. J. Am. Coll Cardiol (1998) 32:2003–2010.
   PubMed Web of Science ®Google Scholar
• CANNON CP, MCCABE CH, WILCOX RG et al.: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes. (OPUS-TIMI 16) Trial. Circulation (2000) 102:149–156.
   Google Scholar
• •An early large scale trial of an oral GP IIbi ha inhibitor in unstable angina that showed no net clinical benefit, an excess of mortality and an increase in bleeding complications.
   Google Scholar
• SYMPHONY INVESTIGATORS: Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet (2000) 55:337–345.
   Google Scholar
• •A subsequent trial of another oral GP IIbi ha antagonist in unstable angina. Again, no benefit and increased mortality.
   Google Scholar
• SECOND SYMPHONY INVESTIGATORS: Randomised trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation (2001) 103:1727–1733.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, EASTON JD, AMARENCO P et al.: Design of the blockade of the glycoprotein IIWIlla receptor to avoid vascular occlusion (BRAVO) trial. Am. Heart (2000) 139:927–933.
   PubMed Web of Science ®Google Scholar
• BRENER SJ, BARR LA, BURCHENAL JEB et al: Randomised, placebo-controlled trial of platelet glycoprotein IIWIlla blockade with primary angioplasty for acute myocardial infarction: ReoPro and Primary PTCA Organisation and Randomised Trial (RAPPORT) Investigators. Circulation (1998) 98:734–741.
   PubMed Web of Science ®Google Scholar
• NEUMANN FJ, BLASINI R, SCHMITT C et al.: Effect of glycoprotein IIWIlla receptor blockade on recovery of coronary flow and left ventricular function after placement of coronary artery stents in acute myocardial infarction. Circulation (1998) 98(24)2695–2701.
   Google Scholar
• NEUMANN FJ, KASTRATI A, SCHMITT C et al.: Effect of glycoprotein receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. j Am. Coll. Cardiol. (2000) 35(4):915–921.
   PubMed Web of Science ®Google Scholar
• MONTALESCOT G, BARRAGAN P, WITTENBERG 0 et al: For the ADMIRAL INVESTIGATORS. Platelet glycoprotein IIWIlla inhibition with coronary stenting for acute myocardial infarction. N Engl. j Med. (2001) 344(25):1895–1903.
   Google Scholar
• ••A trial of adjunctive abciximab in patientsundergoing stenting for AMT. It demonstrated substantial clinical benefit at 30 days and 6 months.
   Google Scholar
• STONE G: Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC). 72nd Session of the American Heart Association. Atlanta, Georgia, USA, 7–10 November, 1999 (Abstract).
   Google Scholar
• ••A factorially designed trial of PTCA (withand without abciximab) and stenting (with and without abciximab) in patients undergoing primary PCT for AMI. There was no benefit in death /MI/any TVR at 6 months when abciximab was added to stenting, but acute ischaemic endpoints were favorably affected by combining stent and abciximab.
   Google Scholar
• SCHOMIG A, KASTRATI A, DIRSCHINGER J et al: Coronary stenting plus platelet glycoprotein IIWIlla blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl. Med. (2000) 343(6):385–391.
   Google Scholar
• GOLD HK, GARABEDIAN HD, DINSMORE RE et al.: Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation (1997) 95(7):1755–1759.
   PubMed Web of Science ®Google Scholar
• ANDERSON HV, KIRKEEIDE RL, KRISHNASWAMI A et al: Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. j Am. Coll. Cardiol (1994) 23(5):1031–1037.
   PubMed Web of Science ®Google Scholar
• VAN DEN MERKHOF LFM, ZULSTRI OLSSON H et al: Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. Am. Coll. Cardiol (1999) 33:1528–1532.
   PubMed Web of Science ®Google Scholar
• KLEIMAN N, OHMAN E, CALIFF R et al.: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 FBA after thrombolytic therapy: results of the Thrombolysis in Myocardial Infarction (TAMI) 8 pilot study. j Am. Coll. Cardiol (1993) 22:381–389.
   PubMed Web of Science ®Google Scholar
• VERSTRAETE M: Synthetic inhibitors of platelet glycoprotein IIWIlla in clinical development. Circulation (2000) 101:e76.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of all the newer, investigational GPblockers.
   Google Scholar
• OHMAN EM, KLEIMAN NS, GACIOCH G et al.: Combined accelerated tissue plasminogen activator and platelet glycloprotein IIWIlla receptor blockade with integrilin in acute myocardial infarction. Circulation (1997) 95:846–854.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM, GIUGLIANO RP, GIBSON CM et al: For the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis; results of the Thrombolysis and Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators. Circulation (1999) 99(21): 2720–2732.
   Google Scholar
• STRATEGIES FOR PATENCY ENHANCEMENT IN THE EMERGENCY DEPARTMENT (SPEED) GROUP: Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation (2000) 101:2788–2794.
   PubMed Web of Science ®Google Scholar
• HERMANN HC, MOLITERNO DJ, OHMAN EM et al.: Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 PILOT) Trial. J Am. Coll. Cardiol (2000) 36(5):1489–1496.
   PubMed Web of Science ®Google Scholar
• ZEYMER U: Oral presentation. ESC 1999, Barcelona, Spain.
   Google Scholar
• BRENER SJ, ADGEY JA, ZEYMER U et al.: Combination low-dose t-PA and eptifibatide for acute myocardial inarction - Final results of the Intro-AMI Study. Circulation (2000) 102(18) (Suppl. II):599–600.
   Google Scholar
• THE GUSTO V INVESTIGATORS: Reperfusion therapy for acute myocardial infarction with flbrinolytic therapy or combination reduced flbrinolytic therapy and platelet glycoprotein IIWIlla inhibition: the GUSTO V randomised trial. Lancet (2001) 357:1905–1914.
   PubMed Web of Science ®Google Scholar
• ••The first large-scale efficacy-powered trial ofcombination therapy with reduced dose fibrinolytic therapy (r-PA) and abciximab versus standard fibrinolytic therapy. There was no significant effect on mortality, but recurrent infarction was reduced with combination therapy.
   Google Scholar
• THE ASSESSMENT OF THE SAFETY AND EFFICACY OF A NEW THROMBOLYTIC REGIMEN (ASSENT)-3 INVESTIGATORS: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358:605-613. A three-arm study comparing standard fibrinolytic therapy (TNK plus UFH), half dose TNK plus abciximab (with UFH) and standard TNK plus enoxaparin (instead of UFH). Composite clinical events in both experimental arms were significnntly reduced; similar to GUSTO V, mortality was unaffected.
   Google Scholar
• ANTMAN E: Oral Presentation. ESC 2001, Stockholm, Sweden.
   Google Scholar